Lisata Therapeutics Inc (LSTA)

[F1ash]

BASKING RIDGE, N.J. (August 2, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will release financial results for the three and six months ended June 30, 2018 after close of the U.S. financial markets on Thursday, August 9, 2018.

Caladrius’ management will host a conference call for the investment community beginning at 4:30 p.m. ET on Thursday, August 9, 2018 to discuss the financial results, provide a company update and answer questions.

Shareholders and other interested parties may participate in the conference call by dialing [phone] (domestic), or [phone] (international), and providing conference ID: 8899285. The call will also be broadcast live on the Internet via the Company’s website at www.caladrius.com/investors/news-events.

For those unable to participate on the live conference call, a replay will be available through August 15, 2018, and can be accessed by dialing [phone] or [phone]. All listeners should provide the following replay access code: 8899285.

The webcast replay will be archived on the Company’s website for 90 days at www.caladrius.com.